Full Text:
<2091>
CLC number: R730.2
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2019-06-23
Cited: 0
Clicked: 3309
Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology
| ||||||||||||||
Xinguo Jiang. Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology[J]. Journal of Zhejiang University Science B, 2020, 21(1): 1-2.
@article{title="Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology",
author="Xinguo Jiang",
journal="Journal of Zhejiang University Science B",
volume="21",
number="1",
pages="1-2",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1910003"
}
%0 Journal Article
%T Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology
%A Xinguo Jiang
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 1
%P 1-2
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1910003
TY - JOUR
T1 - Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology
A1 - Xinguo Jiang
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 1
SP - 1
EP - 2
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1910003
Abstract: This special feature contains three review articles that summarize recent advances pertaining to tumor immunobiology. Normalization of antitumor immunity through checkpoint inhibitors has achieved significant clinical success and benefited many cancer patients. However, not all cancer patients respond to these treatments, and among the responders, some may develop resistance and others may suffer autoimmunity that requires intervention. Tumor immunotherapy holds promise for further improving the survival of cancer patients, but deeper understanding of immunological networks that regulate anti- and pro-tumor immunity is needed. The review papers collected in this issue cover a few topics that may stimulate future interest in the relevant research field.
[1]Chen C, Liu JM, Luo YP, 2020. MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):12-28.
[2]Huang H, Wu HW, Hu YX, 2020. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):29-41.
[3]Jiang X, 2020. Lymphatic vasculature in tumor metastasis and immunobiology. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):3-11.
Open peer comments: Debate/Discuss/Question/Opinion
<1>